Driehaus Capital LEGN Position
Exited6-Fund ConvergenceDriehaus Capital exited their position in Legend Biotech Corporation (LEGN) in Q1 2024, after holding the stock for 3 quarters.
The position was first reported in Q3 2023 and has been tracked across 3 quarterly 13F filings.
LEGN is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 24.7% of float with 9.7 days to cover, indicating significant bearish positioning against the stock.
About Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Full company profile →Short Interest
24.7%
9.7 days to cover
Driehaus Capital LEGN Position History
Frequently Asked Questions
Does Driehaus Capital own LEGN?
No. Driehaus Capital exited their position in Legend Biotech Corporation (LEGN) in Q1 2024. They previously held the stock for 3 quarters.
How many hedge funds own LEGN?
6 specialist biotech hedge funds currently hold LEGN, including RA Capital Management, Deerfield Management, Boxer Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy LEGN?
Driehaus Capital's position in LEGN was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's LEGN position increasing or decreasing?
Driehaus Capital completely exited their LEGN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LEGNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →